$MTVA News

MTVA: Dose Titration Complete in Phase 1 Part 3 Study of DA-1726

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

MetaVia Q2 EPS $(0.90) Misses $(0.82) Estimate

HC Wainwright & Co. Reiterates Buy on MetaVia, Maintains $20 Price Target

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

MetaVia Says All Enrolled Active Patients In Part 3 Of Its Phase 1 Clinical Trial Evaluating DA-1726 For Obesity Treatment Completed Dose Titration, Now Receiving Highest Target Doses In Both Study Cohorts

MetaVia Files Prospectus For Offering $4M Common Shares

OTC Markets Life Sciences Investor Forum: MetaVia CEO HH Kim and CFO Marshall Woodworth with Zacks SCR's David Bautz

MTVA: Vanoglipel and DA-1726 Data Presented at ADA 2026 Scientific Sessions

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

MetaVia Reports Up To 9.1% Weight Loss In Phase 1 DA-1726 Study, Showcases Combination Data For Metabolic Disease Programs At ADA 2026

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

MetaVia To Present Data On Obesity, Metabolic Therapies At Emerging Growth Conference

MTVA: No Evidence for Changes in Cardiovascular Parameters in Phase 1 Trial of DA-1726

MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH

MetaVia Highlights New Phase 1 Data On DA-1726, Dual Oxyntomodulin Analog Agonist Targeting GLP1R And GCGR, In Late-Breaking Poster Presentation At EASL 2026

Why MetaVia Stock Is Surging On Friday?

Why MetaVia Stock Is Falling On Thursday?

MTVA: Multiple Upcoming Presentations to Highlight DA-1726 and Vanoglipel